Stifel has upgraded Inspire Medical Systems Inc (INSP) to a Buy rating from Hold, signaling a more favorable outlook on the company's prospects. The upgrade, effective November 23, 2025, comes as Inspire Medical Systems continues to develop innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Currently priced at $117.29, the company's market capitalization stands at $2.4 billion, with a trailing P/E ratio of 53.89 and an EPS of 1.47.
Inspire Medical Systems, headquartered in Golden Valley, Minnesota, specializes in FDA-approved neurostimulation technology designed to treat moderate to severe OSA. Its proprietary Inspire therapy offers a novel closed-loop solution that continuously monitors a patient’s breathing, delivering mild hypoglossal nerve stimulation to maintain an open airway. The company markets its Inspire system to hospitals and ambulatory surgery centers in the U.S. and select international markets, including Europe and Japan.
This upgrade reflects an analyst sentiment shift that may be driven by improved fundamentals or better-than-expected business performance. Such decisions reflect a growing confidence in the company’s strategic direction, which is crucial as it prepares for upcoming earnings reports. Inspire Medical Systems is set to announce its next earnings on August 3, 2026, with an expected EPS of $0.33 and revenue of $248.9 million, following a strong Q3 2025 performance that beat estimates by 271.7%.
Analyst ratings, while informative, are based on research assumptions and should be considered among various factors when making investment decisions. The current analyst consensus for Inspire Medical Systems remains a Buy, with 4 Strong Buy, 10 Buy, and 12 Hold ratings out of 26 total analysts as of November 1, 2025.